Author Archives: admin

Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome – The…

By adminApril 12, 2020Stem Cell Treatment

WARREN, N.J., April 9, 2020 /PRNewswire/ --Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).

This announcement builds on recent pioneering work by Celularity for the use of its proprietary CYNK-001 for the treatment of the SARS-CoV-2 virus that causes the coronavirus disease, COVID-19, and extends this application of the technology to ARDS. The U.S. Food and Drug Administration recently cleared Celularity's investigational new drug application (IND 019650) to evaluate CYNK-001's safety, tolerability, and efficacy for the treatment of COVID-19.

ARDS, the most devastating complication of COVID-19, is a serious inflammatory lung injury that causes hypoxemia, or below-normal oxygen level in the blood. Hypoxemia can lead to multi-organ system failure and death. Recent findings indicate that ARDS may develop in as many as 17-29% of COVID-19 patients who are hospitalized with pneumonia.

Celularity founder and Chief Executive Officer, Dr. Robert Hariri, said, "This promising, novel approach to treating COVID-19 and the pulmonary complications associated with this infection may unlock a powerful new therapeutic option for patients. The exceptional expertise in pulmonary disease, cellular medicine, and manufacturing makes this strategic collaboration particularly well suited to tackle this urgent, global medical crisis."

Under the amended collaborative agreement, Celularity will seek regulatory approval for CYNK-001 in COVID-19, and Lung Biotechnology will seek regulatory approval for CYNK-001 in ARDS. Lung Biotechnology has global rights under the amended collaborative agreement to commercialize CYNK-001 in COVID-19 and ARDS. The collaboration will be governed by a Joint Steering Committee to oversee development and commercialization activities. Financial terms were not disclosed.

Celularity's CYNK-001 is the only cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy being developed from placental hematopoietic stem cells and is being investigated as a potential treatment option for various hematologic cancers and solid tumors, and is the first cell therapy granted an IND to treat COVID-19. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and virally infected cells and interacting with adaptive immunity. CYNK-001 cells derived from the postpartum placenta have been shown to be well-tolerated in early clinical trials and are currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM).

Media and Investor RelationsMedia Contact:Factory PRcelularity@factorypr.com

Investor Relations Contact:John R. Haines, Executive Vice Presidentjohn.haines@celularity.com

About Celularity: Celularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory, infectious, and age-related diseases. To learn more, please visit http://www.celularity.com.

Forward-Looking Statements: This press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks, and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of the original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

UC San Diego to advance stem cell therapies in new space station lab – – KUSI

By adminApril 12, 2020Stell Cell Research

April 9, 2020

Posted: April 9, 2020

Updated: 5:22 PM

KUSI Newsroom

SAN DIEGO (KUSI) UC San Diego and Space Tango receive NASA award to develop first dedicated stem cell research laboratory within the International Space Station.

UCSDs website reports, A three-year, nearly $5 million award from NASA will allow researchers at the Sanford Stem Cell Clinical Center at UC San Diego Health, Sanford Consortium for Regenerative Medicine and their partners at Space Tango to develop a new integrated space stem cell orbital research laboratory within the International Space Station (ISS) and launch three collaborative research projects within it.

Stem cells self-renew, generating more stem cells, and specialize into tissue-specific cells, such as blood, brain and liver cells, making them ideal for biological studies far from Earths resources. The goal of the new effort is to leverage microgravity and these unique properties of stem cells to better understand how space flight affects the human body. The studies will also inform how aging, degenerative diseases, cancers and other conditions develop in a setting with increased exposure to ionizing radiation and pro-inflammatory factors. The findings from these studies may speed the development of new therapeutics for a broad array of degenerative diseases on Earth.

Dr. Catriona Jamieson, the lead researcher on this NASA award story, visited KUSI News to tell us all about it.

For more information, click here.

More here:
UC San Diego to advance stem cell therapies in new space station lab - - KUSI

Stem Cell Banking Storage Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Science In Me

By adminApril 12, 2020Stell Cell Research

New Jersey, United States:The new report has been added by Market Research Intellect to provide a detailed overview of the Stem Cell Banking Storage Market. The study will help to better understand the Stem Cell Banking Storage industry competitors, the sales channel, Stem Cell Banking Storage growth potential, potentially disruptive trends, Stem Cell Banking Storage industry product innovations and the value / volume of size market (regional / national level, Stem Cell Banking Storage- Industrial segments), market share of the best actors / products.

Information has been added to the report to provide a realistic view of the industry based on data from Stem Cell Banking Storage manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Stem Cell Banking Storage branch. Market participants can use the report to take a look at the future of the Stem Cell Banking Storage market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=181604&utm_source=SI&utm_medium=888

The report examines the competitive environment scenario observed with key players in Stem Cell Banking Storage sales, the profile of their business, their earnings, their sales, their business tactics, and the forecasting situations of the Stem Cell Banking Storage sales industry. According to studies, the Stem Cell Banking Storage sales market is very competitive and diverse due to global and local suppliers.

The Stem Cell Banking Storage Sales Market Report mainly contains the following Manufacturers:

Market Competition

The competitive landscape of the Stem Cell Banking Storage market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Stem Cell Banking Storage market, highlighting their key commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Report Highlights

Assessment of sales channels

innovation trends

sustainability strategies

Niche market trends

Market entry analysis

market size and forecast

The geographic department provides data that give you an overview of the turnover of companies and sales figures for the growth activity Stem Cell Banking Storage for electrical meters. Here are the strengths of the geographic divisions: North America (United States, Canada and Mexico), Europe (Germany, Spain, France, Great Britain, Russia and Italy and more), Asia-Pacific (China, Japan, Korea, India and Southeast Asia) and more ), South America (Brazil, Argentina, Colombia), the Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa) and ROW.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=181604&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Stem Cell Banking Storage Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Banking Storage Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Banking Storage Market, By Deployment Model5.1 Overview

6 Stem Cell Banking Storage Market, By Solution6.1 Overview

7 Stem Cell Banking Storage Market, By Vertical7.1 Overview

8 Stem Cell Banking Storage Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Banking Storage Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/global-stem-cell-banking-storage-market-size-forecast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Stem Cell Banking Storage Market Size, Stem Cell Banking Storage Market Growth, Stem Cell Banking Storage Market Forecast, Stem Cell Banking Storage Market Analysis, Stem Cell Banking Storage Market Trends, Stem Cell Banking Storage Market

See the original post:
Stem Cell Banking Storage Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me

Hematopoietic Stem Cell Transplantation (HSCT) Market Information, Figures and Analytical Insights 2019 2025 – Germany English News

By adminApril 12, 2020Stell Cell Research

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Hematopoietic Stem Cell Transplantation (HSCT) market. We have also provided absolute dollar opportunity and other types of market analysis on the global Hematopoietic Stem Cell Transplantation (HSCT) market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Hematopoietic Stem Cell Transplantation (HSCT) market. All findings and data on the global Hematopoietic Stem Cell Transplantation (HSCT) market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Hematopoietic Stem Cell Transplantation (HSCT) market available in different regions and countries.

Request Sample Report @https://www.mrrse.com/sample/9594?source=atm

The authors of the report have segmented the global Hematopoietic Stem Cell Transplantation (HSCT) market as per product, application, and region. Segments of the global Hematopoietic Stem Cell Transplantation (HSCT) market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Hematopoietic Stem Cell Transplantation (HSCT) market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Companies Mentioned in the Report

The report profiles key manufacturers in the hematopoietic stem cell transplantation (HSCT) Market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include Regen Biopharma, Inc., Escape Therapeutics, Inc., Lonza Group Ltd., and Pluristem Therapeutics Inc.

The global hematopoietic stem cell transplantation (HSCT) Market has been segmented as follows:

By Transplant Type

By Disease Indication

By Application

By Region

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/9594?source=atm

Hematopoietic Stem Cell Transplantation (HSCT) Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Hematopoietic Stem Cell Transplantation (HSCT) Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Hematopoietic Stem Cell Transplantation (HSCT) Market in South, America region is also expected to grow in near future.

The Hematopoietic Stem Cell Transplantation (HSCT) Market report highlights is as follows:

This Hematopoietic Stem Cell Transplantation (HSCT) market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Hematopoietic Stem Cell Transplantation (HSCT) Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Hematopoietic Stem Cell Transplantation (HSCT) Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Hematopoietic Stem Cell Transplantation (HSCT) Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

Buy This Report @ https://www.mrrse.com/checkout/9594?source=atm

See the original post here:
Hematopoietic Stem Cell Transplantation (HSCT) Market Information, Figures and Analytical Insights 2019 2025 - Germany English News

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To…

By adminApril 12, 2020Stell Cell Research

The Autologous Stem Cell and Non-Stem Cell Based Therapies market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Autologous Stem Cell and Non-Stem Cell Based Therapies market study offers reliable and authentic projections regarding the technical jargon.

All the players running in the global Autologous Stem Cell and Non-Stem Cell Based Therapies market are elaborated thoroughly in the Autologous Stem Cell and Non-Stem Cell Based Therapies market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Autologous Stem Cell and Non-Stem Cell Based Therapies market players.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2439434&source=atm

The major players profiled in this report include:U.S. STEM CELL, INC.Brainstorm Cell TherapeuticsCytoriDendreon CorporationFibrocellLion BiotechnologiesCaladrius BiosciencesOpexa TherapeuticsOrgenesisRegenexxGenzymeAntriaRegeneusMesoblastPluristem Therapeutics IncTigenixMed cell EuropeHolostemMiltenyi Biotec

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Autologous Stem Cell and Non-Stem Cell Based Therapies for each application, including-Neurodegenerative DisordersAutoimmune Diseases Cancer and TumorsCardiovascular Diseases

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2439434&source=atm

Objectives of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Study:

The Autologous Stem Cell and Non-Stem Cell Based Therapies market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Autologous Stem Cell and Non-Stem Cell Based Therapies market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Autologous Stem Cell and Non-Stem Cell Based Therapies market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2439434&licType=S&source=atm

After reading the Autologous Stem Cell and Non-Stem Cell Based Therapies market report, readers can:

View original post here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To...

COVID-19 Impact on Stem Cell Media Market Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 -…

By adminApril 12, 2020Stell Cell Research

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Stem Cell Media Market which would mention How the Covid-19 is Affecting the Stem Cell Media Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Stem Cell Media Players to Combat Covid-19 Impact.

The Global Stem Cell Media Market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, Titled [Stem Cell Media Market Research Report 2020], offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Stem Cell Media market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Global Stem Cell Media Market is valued at USD XX million in 2020 and is projected to reach USD XX million by the end of 2026, growing at a CAGR of XX% during the period 2020 to 2026.

Top Key Players of the Global Stem Cell Media Market:Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza, GE Healthcare, Miltenyi Biotec, Corning, CellGenix, Takara, PromoCell, HiMedia

>>Get Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures):https://www.qyresearch.com/sample-form/form/1637298/global-stem-cell-media-market

The Essential Content Covered in the Global Stem Cell Media Market Report:Top Key Company Profiles.Main Business and Rival InformationSWOT Analysis and PESTEL AnalysisProduction, Sales, Revenue, Price and Gross MarginMarket Size And Growth RateCompany Market Share

Global Stem Cell Media Market Segmentation By Product:Pluripotent Stem Cell Culture, Hematopoietic Stem Cell Culture, Mesenchymal Stem Cell Culture, Others

Global Stem Cell Media Market Segmentation By Application:Scientific Research, Industrial Production

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Stem Cell Media Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Stem Cell Media Market in South, America region is also expected to grow in near future.

Key questions answered in the report*What will be the market size in terms of value and volume in the next five years?*Which segment is currently leading the market?*In which region will the market find its highest growth?*Which players will take the lead in the market?*What are the key drivers and restraints of the markets growth?

>>>Request Customization of Report :https://www.qyresearch.com/customize-request/form/1637298/global-stem-cell-media-market

Table of Content

1 Stem Cell Media Market Overview1.1 Stem Cell Media Product Overview1.2 Stem Cell Media Market Segment by Type1.2.1 Pluripotent Stem Cell Culture1.2.2 Hematopoietic Stem Cell Culture1.2.3 Mesenchymal Stem Cell Culture1.2.4 Others1.3 Global Stem Cell Media Market Size by Type (2015-2026)1.3.1 Global Stem Cell Media Market Size Overview by Type (2015-2026)1.3.2 Global Stem Cell Media Historic Market Size Review by Type (2015-2020)1.3.2.1 Global Stem Cell Media Sales Market Share Breakdown by Type (2015-2026)1.3.2.2 Global Stem Cell Media Revenue Market Share Breakdown by Type (2015-2026)1.3.2.3 Global Stem Cell Media Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Stem Cell Media Market Size Forecast by Type (2021-2026)1.3.3.1 Global Stem Cell Media Sales Market Share Breakdown by Application (2021-2026)1.3.3.2 Global Stem Cell Media Revenue Market Share Breakdown by Application (2021-2026)1.3.3.3 Global Stem Cell Media Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.2 Europe Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.4 Latin America Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Stem Cell Media Sales Breakdown by Type (2015-2026)1.5 Coronavirus Disease 2019 (Covid-19): Stem Cell Media Industry Impact1.5.1 How the Covid-19 is Affecting the Stem Cell Media Industry1.5.1.1 Stem Cell Media Business Impact Assessment Covid-191.5.1.2 Supply Chain Challenges1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Stem Cell Media Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-191.5.3.1 Government Measures to Combat Covid-19 Impact1.5.3.2 Proposal for Stem Cell Media Players to Combat Covid-19 Impact

2 Global Stem Cell Media Market Competition by Company2.1 Global Top Players by Stem Cell Media Sales (2015-2020)2.2 Global Top Players by Stem Cell Media Revenue (2015-2020)2.3 Global Top Players Stem Cell Media Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Stem Cell Media Manufacturing Base Distribution, Sales Area, Product Type2.5 Stem Cell Media Market Competitive Situation and Trends2.5.1 Stem Cell Media Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Stem Cell Media Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Media as of 2019)2.7 Date of Key Manufacturers Enter into Stem Cell Media Market2.8 Key Manufacturers Stem Cell Media Product Offered2.9 Mergers & Acquisitions, Expansion

3 Global Stem Cell Media Status and Outlook by Region (2015-2026)3.1 Global Stem Cell Media Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Stem Cell Media Market Size Market Share by Region (2015-2020)3.2.1 Global Stem Cell Media Sales Market Share by Region (2015-2020)3.2.2 Global Stem Cell Media Revenue Market Share by Region (2015-2020)3.2.3 Global Stem Cell Media Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Stem Cell Media Market Size Market Share by Region (2021-2026)3.3.1 Global Stem Cell Media Sales Market Share by Region (2021-2026)3.3.2 Global Stem Cell Media Revenue Market Share by Region (2021-2026)3.3.3 Global Stem Cell Media Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Stem Cell Media Market Size YoY Growth (2015-2026)3.4.1 North America Stem Cell Media Revenue YoY Growth (2015-2026)3.4.2 North America Stem Cell Media Sales YoY Growth (2015-2026)3.5 Asia-Pacific Stem Cell Media Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Stem Cell Media Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Stem Cell Media Sales YoY Growth (2015-2026)3.6 Europe Stem Cell Media Market Size YoY Growth (2015-2026)3.6.1 Europe Stem Cell Media Revenue YoY Growth (2015-2026)3.6.2 Europe Stem Cell Media Sales YoY Growth (2015-2026)3.7 Latin America Stem Cell Media Market Size YoY Growth (2015-2026)3.7.1 Latin America Stem Cell Media Revenue YoY Growth (2015-2026)3.7.2 Latin America Stem Cell Media Sales YoY Growth (2015-2026)3.8 Middle East and Africa Stem Cell Media Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Stem Cell Media Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Stem Cell Media Sales YoY Growth (2015-2026)

4 Global Stem Cell Media by Application4.1 Stem Cell Media Segment by Application4.1.1 Scientific Research4.1.2 Industrial Production4.2 Global Stem Cell Media Sales by Application: 2015 VS 2020 VS 20264.3 Global Stem Cell Media Historic Sales by Application (2015-2020)4.4 Global Stem Cell Media Forecasted Sales by Application (2021-2026)4.5 Key Regions Stem Cell Media Market Size by Application4.5.1 North America Stem Cell Media by Application4.5.2 Europe Stem Cell Media by Application4.5.3 Asia-Pacific Stem Cell Media by Application4.5.4 Latin America Stem Cell Media by Application4.5.5 Middle East and Africa Stem Cell Media by Application5 North America Stem Cell Media Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Stem Cell Media Sales Market Share by Country (2015-2020)5.1.2 North America Stem Cell Media Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Stem Cell Media Sales Market Share by Country (2021-2026)5.2.2 North America Stem Cell Media Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Stem Cell Media Market Size YoY Growth (2015-2026)5.3.2 Canada Stem Cell Media Market Size YoY Growth (2015-2026)6 Europe Stem Cell Media Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Stem Cell Media Sales Market Share by Country (2015-2020)6.1.2 Europe Stem Cell Media Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Stem Cell Media Sales Market Share by Country (2021-2026)6.2.2 Europe Stem Cell Media Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Stem Cell Media Market Size YoY Growth (2015-2026)6.3.2 France Stem Cell Media Market Size YoY Growth (2015-2026)6.3.3 U.K. Stem Cell Media Market Size YoY Growth (2015-2026)6.3.4 Italy Stem Cell Media Market Size YoY Growth (2015-2026)6.3.5 Russia Stem Cell Media Market Size YoY Growth (2015-2026)7 Asia-Pacific Stem Cell Media Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Stem Cell Media Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Stem Cell Media Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Stem Cell Media Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Stem Cell Media Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Stem Cell Media Market Size YoY Growth (2015-2026)7.3.2 Japan Stem Cell Media Market Size YoY Growth (2015-2026)7.3.3 South Korea Stem Cell Media Market Size YoY Growth (2015-2026)7.3.4 India Stem Cell Media Market Size YoY Growth (2015-2026)7.3.5 Australia Stem Cell Media Market Size YoY Growth (2015-2026)7.3.6 Taiwan Stem Cell Media Market Size YoY Growth (2015-2026)7.3.7 Indonesia Stem Cell Media Market Size YoY Growth (2015-2026)7.3.8 Thailand Stem Cell Media Market Size YoY Growth (2015-2026)7.3.9 Malaysia Stem Cell Media Market Size YoY Growth (2015-2026)7.3.10 Philippines Stem Cell Media Market Size YoY Growth (2015-2026)7.3.11 Vietnam Stem Cell Media Market Size YoY Growth (2015-2026)8 Latin America Stem Cell Media Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Stem Cell Media Sales Market Share by Country (2015-2020)8.1.2 Latin America Stem Cell Media Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Stem Cell Media Sales Market Share by Country (2021-2026)8.2.2 Latin America Stem Cell Media Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Stem Cell Media Market Size YoY Growth (2015-2026)8.3.2 Brazil Stem Cell Media Market Size YoY Growth (2015-2026)8.3.3 Argentina Stem Cell Media Market Size YoY Growth (2015-2026)9 Middle East and Africa Stem Cell Media Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Stem Cell Media Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Stem Cell Media Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Stem Cell Media Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Stem Cell Media Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Stem Cell Media Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Stem Cell Media Market Size YoY Growth (2015-2026)9.3.3 UAE Stem Cell Media Market Size YoY Growth (2015-2026)

10 Company Profiles and Key Figures in Stem Cell Media Business10.1 Thermo Fisher10.1.1 Thermo Fisher Corporation Information10.1.2 Thermo Fisher Description, Business Overview and Total Revenue10.1.3 Thermo Fisher Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.1.4 Thermo Fisher Stem Cell Media Products Offered10.1.5 Thermo Fisher Recent Development10.2 STEMCELL Technologies10.2.1 STEMCELL Technologies Corporation Information10.2.2 STEMCELL Technologies Description, Business Overview and Total Revenue10.2.3 STEMCELL Technologies Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.2.4 Thermo Fisher Stem Cell Media Products Offered10.2.5 STEMCELL Technologies Recent Development10.3 Merck Millipore10.3.1 Merck Millipore Corporation Information10.3.2 Merck Millipore Description, Business Overview and Total Revenue10.3.3 Merck Millipore Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.3.4 Merck Millipore Stem Cell Media Products Offered10.3.5 Merck Millipore Recent Development10.4 Lonza10.4.1 Lonza Corporation Information10.4.2 Lonza Description, Business Overview and Total Revenue10.4.3 Lonza Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.4.4 Lonza Stem Cell Media Products Offered10.4.5 Lonza Recent Development10.5 GE Healthcare10.5.1 GE Healthcare Corporation Information10.5.2 GE Healthcare Description, Business Overview and Total Revenue10.5.3 GE Healthcare Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.5.4 GE Healthcare Stem Cell Media Products Offered10.5.5 GE Healthcare Recent Development10.6 Miltenyi Biotec10.6.1 Miltenyi Biotec Corporation Information10.6.2 Miltenyi Biotec Description, Business Overview and Total Revenue10.6.3 Miltenyi Biotec Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.6.4 Miltenyi Biotec Stem Cell Media Products Offered10.6.5 Miltenyi Biotec Recent Development10.7 Corning10.7.1 Corning Corporation Information10.7.2 Corning Description, Business Overview and Total Revenue10.7.3 Corning Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.7.4 Corning Stem Cell Media Products Offered10.7.5 Corning Recent Development10.8 CellGenix10.8.1 CellGenix Corporation Information10.8.2 CellGenix Description, Business Overview and Total Revenue10.8.3 CellGenix Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.8.4 CellGenix Stem Cell Media Products Offered10.8.5 CellGenix Recent Development10.9 Takara10.9.1 Takara Corporation Information10.9.2 Takara Description, Business Overview and Total Revenue10.9.3 Takara Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.9.4 Takara Stem Cell Media Products Offered10.9.5 Takara Recent Development10.10 PromoCell10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Stem Cell Media Product Category, Application and Specification10.10.3 PromoCell Stem Cell Media Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 PromoCell Recent Development10.11 HiMedia10.11.1 HiMedia Corporation Information10.11.2 HiMedia Description, Business Overview and Total Revenue10.11.3 HiMedia Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.11.4 HiMedia Stem Cell Media Products Offered10.11.5 HiMedia Recent Development

11 Stem Cell Media Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Stem Cell Media Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Stem Cell Media Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis

12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers

13 Research Findings and Conclusion

14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post here:
COVID-19 Impact on Stem Cell Media Market Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 -...

Lung epithelium model being tested as a platform for COVID-19 research – Drug Target Review

By adminApril 11, 2020Induced Pluripotent Stem Cells

The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.

A biotech company has announced they are testing whether their human lung epithelium model could be used as a platform for investigating SARS-CoV-2 infection and developing and evaluating potential antiviral strategies for COVID-19.

Newcells Biotech based their lung epithelium organoid on human induced pluripotent stem cells (hiPSC) and have been developing the model for two years. The model contains basal epithelia, ciliated and secretory cells (goblet and club cells) organised in a stratified epithelium. The company stated it has already confirmed it expresses the mRNA for the angiotensin converting enzyme (ACE2) which SARS-CoV, the coronavirus causing COVID-19, uses to infect cells. It is currently determining whether ACE2 is present on the surface of cells in the model.

Once this is confirmed, the enterprise intends to challenge the model with the virus to confirm it can infect and virally replicate. The company is working with two laboratories to design these protocols.

According to Newcells, before the COVID-19 pandemic it had been developing a hiPSC-derived model of the upper airway for toxicology testing of environmental pollutants. This model has been shown to respond to airborne particles with cytokine responses and changes in gene expression.

The enterprise said it is working rapidly to demonstrate the utility of its assays for COVID-19 research and is interested in working with collaborators.

Related topicsCell-based assays, Disease research, Drug Development, Drug Discovery, Drug Targets, Immunology, Organoids, Protein Expression, Proteomics, Research & Development, Stem Cells

Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion – Clinical OMICs News

By adminApril 11, 2020Induced Pluripotent Stem Cells

Johnson & Johnsons Janssen Biotech will partner with Fate Therapeutics to create cell-based cancer immunotherapies derived from induced pluripotent stem cells (iPSCs), through a collaboration that could generate more than $3 billion for the San Diego cellular immunotherapy developer.

Janssen will bring to the partnership its proprietary antigen binding domains, with the aim of creating product candidates for up to four tumor associated antigens for blood and solid cancers.

To create those candidates, Janssen plans to use Fates iPSC product platform to research and develop novel chimeric antigen receptor (CAR) natural killer (NK) and CAR T-cell product candidates to preclinical phases.

The iPSC platform is designed to enable mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments, according to Fate.

Fates platform involves engineering human iPSCs in a one-time genetic modification event, then selecting a single engineered iPSC for maintenance as a clonal master iPSC line. The company says its clonal master iPSC lines are a renewable source for manufacturing cell therapy products that are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment.

Fate said it will advance candidates created through the collaboration to the filing of an IND application, after which Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens.

Fate will have primary responsibility for manufacturing candidates created through the collaboration, with Janssen paying for their cost.

$50M upfront

Janssen agreed to pay Fate $50 million upfront, while another J&J entity, Johnson & Johnson InnovationJJDC, will purchase newly-issued shares of Fates common stock at a price per share of $31.00a 31% premium over Fates closing share price Friday of $22.94.

Janssen also agreed to pay Fate up to $1.8 billion in payments tied to achieving development and regulatory milestonesplus another up to $1.2 billion tied to achieving commercial milestones, as well as double-digit royalties on worldwide commercial sales of products targeting the antigens.

Fate has the right to elect to co-commercialize each collaboration candidate in the United States and share equally in profits and losses in the United States, subject to paying clinical development costs and adjustments in milestone and royalty payments.

Janssen also agreed to reimburse Fate for all activities conducted under the collaboration.

The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen binding domains, while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Fate president and CEO Scott Wolchko said Thursday in a statement.

Cell therapy restores mobility and sensations in rodent models of stroke – FierceBiotech

By adminApril 11, 2020Stem Cell Treatment

Scientists at Lund University in Sweden showed long ago they could reprogram human cells into nerve cells and implant them into the brains of rats after a stroke. But would the cells form the vital connections needed to restore mobility and sensations like touch?

Now, they have early evidence that the answer to that question isyes. The Lund team turned skin cells into nerve cells, transplanted them into the brains of the rodent stroke models and observed them for six months. The new cells repaired the damage caused by strokes in the animals, the researchers reported in the journal PNAS.

The Lund University team transplanted the reprogrammed skin cells into the rats cerebral cortices, the region of the brain thats most commonly damaged by stroke. Then they used electron microscopy and other technologies to track the cells. That allowed them to see that the cells were making the connections needed to repair damaged nerve circuits.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

We have been able to see that the fibers from the transplanted cells have grown to the other side of the brain, the side where we did not transplant any cells, and created connections, said co-author Zaal Kokaia, professor of neurology at Lund, in a statement.

RELATED: Restoring neurons to preserve memory after heart attack or stroke

Cell therapy has been proposed for treating stroke damage in the past, but efforts to make it a reality have hit some roadblocks. A stem cell therapy being developed by British biotech ReNeuron failed to hit its primary trial endpoint of improving arm and leg movements. ReNeuron has since turned in better results from a trial of its cell therapy for improving vision in patients with retinitis pigmentosa.

Meanwhile, academic researchers are testing a variety of other therapies aimed at repairing stroke damage. Last year, for example, Stanford researchers showed that blocking a particular microRNA prompted star-shaped brain cells called astrocytes to become neurons, which helped restore memory in rats.

The Lund team is now planning additional animal trials to study how their transplanted cells affect memory and other intellectual functions, they said. They will also watch the rats closely to make sure they arent experiencing side effects, and theyll study the impact of the transplants on regions of the brain.

Read the rest here:
Cell therapy restores mobility and sensations in rodent models of stroke - FierceBiotech

Searching for an effective Covid-19 treatment: promise and peril – STAT

By adminApril 11, 2020Stem Cell Treatment

In response to the most serious global health threat in a century, the worlds biomedical establishment is unleashing an unprecedented response to the Covid-19 pandemic, rapidly increasing resources aimed at finding safe and effective treatments for the disease. But without careful attention to the pitfalls that can befall biomedical research and regulatory decision-making during a time of crisis, a lot can go wrong.

On March 28, the FDA provided emergency use authorization for hydroxychloroquine a medicine approved for treating malaria for people hospitalized with Covid-19. It also however, told health providers that the optimal dose and duration of treatment were unknown. The authorization did not identify any clinical study on which this approval was based, and while hydroxychloroquine may affect viral replication and might ultimately prove beneficial, its impact on health outcomes among patients with Covid-19 is currently unclear.

Against this potentially worrisome action, the scope of the search for a new treatment to mitigate or cure Covid-19 is breathtaking. One recent listing identified more than 70 candidate molecules, including 15 antivirals, potent suppressants of the human immune system, and high-risk oncology treatments already approved by the FDA to treat other conditions.

The National Institutes of Healths ClinicalTrials.gov lists more than 100 clinical investigations focused on Covid-19 from around the world, with sponsors that include medical centers, pharmaceutical companies, and national research institutes. In time, it is likely we will see direct-acting antivirals tailored to the most vulnerable molecular targets on the SARS-CoV-2 virus.

But this extraordinary effort is lacking international coordination, which may yield counterproductive competition among countries with biotechnology industries. The coronavirus does not respect national boundaries; neither can the development of new treatments, which are already being tested in more than 15 countries. As a first step, the biomedical community needs to insist on consistent use of central registries of clinical studies and on early sharing of complete details of both successful and failed studies, and not withhold important scientific evidence as proprietary information.

Acting against this effort is a growing industry fueled by fear and panic. Medical history has taught us that when people get sick and scared they will take practically anything. For centuries, worthless and sometimes harmful treatments, ranging from arsenic to swamp root, have been promoted by everyone from charlatans to well-meaning clinicians.

In an emergency situation such as this one, attention will naturally turn to repurposing already available products, which makes good sense. But we need to let scientists do their jobs. In too many past cases, drugs have been widely used off-label or based on a positive response in a narrow laboratory or clinical measure only to have independent analysis later show that the treatments do more harm than good or target the wrong patient population. For example, a family of anti-arrhythmic drugs that was effective in stopping asymptomatic irregular heartbeats was subsequently found to increase the risk of cardiac arrest when given to heart attack survivors.

The biomedical establishment must speak with a clear voice about the need to adequately test new drug treatments for Covid-19 and to subject that evidence to independent evaluation by the FDA.

Other pitfalls await those too ready to embrace a new treatment. One is the power of the placebo effect. Among individuals participating in clinical trials, those unaware they are receiving an inactive placebo can show substantial improvement, sometimes equal to 80% of the apparent treatment effect of the active therapy. The placebo effect has been documented in clinical trials assessing health benefits that range from improvement in subjective psychiatric symptoms to objective laboratory results.

Who has not read media reports about an individuals miraculous recovery at the hands of a caring physician trying an entirely new approach to treatment? Independent investigation of the case confirms the striking improvement was real. But it turns out to be a dramatic example of idiosyncratic recoveries that can be neither explained nor duplicated in other patients.

The coming flood of research from trials now or soon to be underway should lead us toward realistic and objective measures of the two fundamental properties of every therapeutic drug: benefit and harm.

A drug that shows disease activity against SARS-CoV-2 could prove too toxic to give to Covid-19 patients with worsening pneumonia. A claim that a drug reduces viral load could be valid, but its health benefits or harms could depend on when in the cycle of infection it is used. A drug intended for those with mild-to-moderate symptoms but who are otherwise healthy must be of low toxicity because it will be given to many patients who might have otherwise recovered on their own, while it may be more acceptable to offer drugs with more severe toxicities to patients at higher risk of death.

Another fundamental aspect of all drug testing is encouraging when it comes to Covid-19 research. As the first antibiotics for pneumonia taught us in the 1930s, a dramatically effective treatment for an acute illness can be convincingly demonstrated in a small number of patients observed over a few weeks time. The chances of discovering and documenting such a treatment grow if we also greatly increase the number of patients enrolled in clinical studies.

In the 1980s, during the HIV epidemic, patient advocacy groups not only helped shape the way clinical trials of the disease were conducted but served as a strong force for recruiting patients into trials of investigational drugs. A broad network of trial participants helped accelerate testing of drugs in the pipeline.

In the case of pediatric cancer, a collaborative professional network was established decades ago to ensure that all patients are enrolled in clinical trials at the time of initial diagnosis. These patients then get top-quality care and generate data to help future patients.

Supported by these forces, it is not surprising that both HIV and pediatric cancer have seen remarkable advances in care over the last 30 years.

It is a false choice to think that we can either have expeditious treatment options for SARS-CoV-2 or we can have rigorous testing of them. We can have both. Achieving that goal, however, will require avoiding missteps such as widely promoting unproven products so fearful people begin using them in inconsistent ways outside of the research enterprise. Instead, we will need international coordination of scientific goals, transparency of results, comprehensive participation in clinical research, and trials that evaluate meaningful outcomes. Doing that can ensure that any treatments that are developed do, in fact, benefit the patients who receive them.

G. Caleb Alexander, M.D., is a professor of epidemiology and medicine at the Johns Hopkins Bloomberg School of Public Health. Aaron S. Kesselheim, M.D., is a professor of medicine at Brigham and Womens Hospital and Harvard Medical School. Thomas J. Moore is a lecturer at George Washington University Milken Institute School of Public Health.

Follow this link:
Searching for an effective Covid-19 treatment: promise and peril - STAT